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Abstract Head and neck (H&N) cancer is an aggressive
disease and the incidence has increased in younger popu-
lation worldwide. Tumour TNM staging is the main basis
for treatment decision despite significant variation in
clinical outcome. Survival time of these patients has mar-
ginally improved during the last 30 years. Various
biomarkers with cumbersome analysis, high cost, time
consumption and requirement of special laboratory facili-
ties have been investigated. However, none of these
biomarkers have been shown to be suitable to use for
individual H&N cancer patient treatment selection in the
clinic. For practical use in clinical settings, the given
biomarkers must be simple to analyse, rapid, cost effective
and available in routine laboratories. With this intension,
we suggested the combination of standard TNM staging
and biomarkers associated with inflammation such as
neutrophils, neutrophil to lymphocyte ratio, plasma C-re-
active protein or plasma tumour necrosis factor alpha
(TNFa) and single-nucleotide polymorphism in TNFa
rs1800629 using blood-based analysis. The optimal treat-
ment outcome of H&N cancer by using combination of
TNM stage and these blood-based biomarkers for indi-
vidual patient selection need further investigation.
Keywords Head and neck cancer  Single-nucleotide
polymorphism  Inflammation  Individualized treatment
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Introduction
Head and neck (H&N) cancer is an aggressive disease and
the incidence is increasing, especially in younger population
worldwide [1, 2]. Relatively high loco-regional recurrent
tumours, derived from local primary tumour or second pri-
mary tumour from the normal-appearing tissue were
observed in these patients [3–5]. Despite aggressive and
advanced treatment regimens, long-term survival in human
papilloma virus (HPV) negative H&N cancer is only mar-
ginally improved during the last 30 years [2, 6–12].
Tumour TNM staging is the primary guide for treatment
modality despite significant heterogeneity in clinical out-
come. Independent from TNM stage, number of circulating
tumour cells, lymphocytes expressing cytolyses granules,
neutrophils, neutrophil to lymphocyte ratio (NLR), plasma
C-reactive protein (CRP), tumour necrosis factor alpha
(TNFa) or downregulated T cell receptor Zeta chain was
associated with the clinical outcome of cancer patients
[13–19].
Prognostic biomarkers for individual patient treatment
selection in the clinical practice need to be established for
optimal clinical outcome of H&N cancer patients. We
emphasize the cost-effective, rapid and automatic blood-
based biomarkers in combination with TNM staging for
individual treatment selection in the clinical setting of this
patient group.
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HPV, cigarette, alcohol, single-nucleotide
polymorphism (SNP) and H&N cancer
Epidemiological data have established that cigarette
smoking, alcohol consumption or HPV infection are the
main risk factors for H&N cancer [20–23]. More than 95%
of these malignant tumours are squamous cell carcinoma,
originating from the mucosal epithelium cells linings of the
upper aero-digestive tract [24]. It is important to point out
that not all HPV infected persons, heavy smokers or high
alcohol consumers develop cancer. The elevated cancer
risk among first-degree relatives of H&N cancer patients
indicated an important role of genetic factors [25, 26].
SNP is the most common source of human genetic vari-
ation in the individual germline DNA. SNP sequence vari-
ation may lead to altered effects of the gene and causes inter-
individual susceptibility to oncogenesis. One SNP, TNFa
rs1800629 is associated with increased risk of H&N cancer,
tumour recurrence and survival time of the patients [27].
HPV is a common sexually transmitted infection and
most of the sexually active women and men worldwide are
infected by low-risk or high-risk HPV in their life time
[22, 28, 29]. HPV infect squamous epithelial cells through
cellular membrane receptors [29–31]. Sexual behaviour,
oral hygiene and smoking are suggested to be related to
oral HPV infection in the healthy individuals [32, 33].
High-risk HPV type might be necessary for tumorigen-
esis but it is not sufficient on its own [22]. Individual host
SNPs influences the susceptibilities to high-risk or low-risk
HPV infection process and outcome of the infection [33].
Generally, virus infected cells will carry virus genome in
the episomal form, maintained at constant copy numbers
and replicated along with host cellular DNA [29, 34]. Host
immune response plays a role in clearance of HPV since
HPV infected epithelial cells are spontaneously regressed
in immunocompetent individuals [22, 35, 36].
The presence of high-risk HPV-DNA is insufficient to
classify accurately tumours as an HPV associated since it
might be present as the passenger, inactive virus and not
the cause of malignancy [37, 38]. The oncogenesis of high-
risk HPV is suggested to occur from integrated high-risk
HPV-DNA in the host DNA [36]. This high-risk, integrated
HPV-DNA acquires the capacity to inhibit cellular differ-
entiation and actively transcribes high-risk HPV oncopro-
teins in host cells [39, 40].
Two techniques, PCR and in situ hybridization (ISH),
are generally used for diagnosis of high-risk HPV status in
biopsy material. The presence of high-risk HPV-DNA
shown by PCR or ISH is, however, insufficient to accu-
rately classify tumours as HPV associated. Fluorescence
in situ hybridization (FISH) could identify whether the
high-risk HPV is oncogenic with integrated HPV-DNA or
inactive with episomal HPV-DNA in the infected cells
[40]. This analysis is, however, not suitable in clinical
practice due to time consumption, high cost and require-
ment of special laboratory facilities.
Cigarette smoking and alcohol consumption are indepen-
dent risk factors but when combined a synergistic effects is
observed [20]. In vitro, combination of smoke extract and
alcohol induces massive normal cell death and this is associ-
atedwith SNPgenotypeof the individual donors [41, 42].High
frequency of HPV infection in multiple dysplastic lesions of
smokers or alcohol users were detected [43–46]. An additive
impact of SNPs, HPV, smoking and alcohol consumption on
risk to develop H&N cancer could be expected [45–48].
Inflammation, SNPs and clinical outcome of H&N
cancer patients
Systemic inflammation from smoking induces massive cell
death in the body might indicate by increasing circulating
neutrophil, NLR, perforin expression in T cells and plasma
CRP or TNFa levels were detected in healthy smokers
(Luetragoon et al., manuscript in preparation). HPV infec-
tion and alcohol consumption could also increase normal cell
death [22, 41, 42, 49]. Independent from etiological point of
view, cell death will release autologous antigens that pro-
voke local and systemic host immune response [33]. Long-
term exposures to these autologous antigenswill upregulated
inflammatory biomarkers, and this seems to be correlated
with specific SNP sequence and not random events [26, 47].
Human solid tumours are generally infiltrated by
inflammatory cells and considered to be a host attempt at
the detection of emerging tumour cells and their elimina-
tion [50]. H&N tumours are among the most highly
immune-infiltrated cancer types. The smoking patient with
tumours harbouring mutation signatures and lower immune
infiltration had a shorter survival time [51, 52].
Elevated frequency and enhanced suppression capacity of
regulatory T cells (Treg) was detected in blood circulation of
H&N cancer patients [53, 54]. Increased levels of circulating
plasma CRP and TNFawas associated with survival of H&N
cancer patient [15–17, 27]. Thus, tumour and the inflam-
matory cells might acquire the immunosuppressive activity
or secretion inflammatory cytokines [55, 56].
Blood-based genetic and inflammation biomarkers
in H&N cancer patients
Peripheral blood contains immune response cells, plasma
proteins, cytokines and variable mediators with wide-
ranging biologic effects. Circulating blood are in direct
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contact with all organs, non-invasive to obtain and suit-
able for transportation. Analysis of SNPs and inflammatory
biomarkers could be simply done using this peripheral
blood sample.
Using only TNM stage as treatment selection might be
practical but not optimal to predict clinical outcome of
H&N cancer patients. Independent from tumour etiological
or TNM stage, SNP in TNFa and elevating number of
inflammatory biomarkers obtained from pre-treatment
peripheral blood sample is associated with the clinical
outcome of H&N cancer patients [7, 15–17, 27]. Analysis
of SNPs and these inflammation biomarkers using periph-
eral blood samples are well established. They are rapid,
cost effective and can be done with automatic equipment,
existing in the routine laboratory.
With intension to be used as biomarkers in clinical
practice, such analysis must be rapid, available in routine
laboratory facility and cost effective. For optimal person-
alized H&N cancer treatment, we propose the pre-treat-
ment blood-based biomarkers with focus on TNFa
rs1800629, neutrophil counts, NLR, plasma CRP and TNFa
in combination with standard pathological diagnosis and
TNM classification for individual H&N cancer patient
treatment selection. The prognostic value of this combi-
nation warrants future clinical investigation.
Conclusion
The impact of genetic variation, smoking, alcohol con-
sumption, HPV infection and HPV integration significantly
influence host immune response [22, 23, 31, 42, 52]. This
could facilitate the formation of an inflammation
microenvironment and systemic inflammation that favours
carcinogenesis and cancer progression in H&N cancer
patients [15, 17, 23, 27]. The clinical significance of SNPs
and systemic inflammatory biomarkers investigated at the
diagnostic time, suggests the possibility of individual
patient treatment selection [7, 15, 16, 18, 27].
The analysis of TNFa rs1800629 and systemic inflam-
matory biomarkers such as plasma CRP, TNFa or neu-
trophil and NLR using blood sample are rapid, cost
effective and require only common facility in the routine
laboratory. Thus, blood-based biomarkers offer an attrac-
tive possibility to use in combination with standard tumour
TNM stage for individual H&N cancer patient treatment
selection in the clinical setting. The prognostic value of
TNM stage combined with these blood-based biomarkers
for treatment selection of H&N cancer patients warrants
further investigation.
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